{Reference Type}: Clinical Trial, Phase II
{Title}: Interleukin-33 antibody failed to demonstrate benefit in a phase II, double-blind, randomized, placebo-controlled study in adult patients with moderate-to-severe atopic dermatitis.
{Author}: Laquer V;Parra V;Lacour JP;Takahashi H;Knorr J;Okragly AJ;James DE;Sims JT;Chang CY;Chao J;Klekotka P;
{Journal}: Br J Dermatol
{Volume}: 187
{Issue}: 4
{Year}: 10 2022
{Factor}: 11.113
{DOI}: 10.1111/bjd.21631
{Abstract}: